CULVER CITY, Calif.--(BUSINESS WIRE)-- ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced treatment with ANKTIVA® (nogapendekin alfa inbakicept-pmln) plus Bacillus ...

Anktiva plus BCG aims to treat BCG-unresponsive NMIBC with papillary disease, potentially reducing radical cystectomy need. The treatment showed high rates of surgery avoidance and disease-free ...

The Scottish Medicines Consortium has approved a new first-line combination therapy for restricted use in adults with unresectable or metastatic urothelial cancer.

The TAR-200 system offering sustained intravesical gemcitabine release shows favorable response and tolerability in both the CIS and papillary-only subgroups with BCG-unresponsive high-risk NMIBC. TAR ...

Before the discovery of newer options and combinations, chemotherapy that included platinum medications like cisplatin or carboplatin was the first choice, says Christopher Wee, MD, a genitourinary ...

The online calculator enhances accessibility, enabling broader application in diverse healthcare settings. Moreover, the genetic findings provide a rationale for closer monitoring of urinary system ...

When you learn you have bladder cancer, it’s only natural to ask: "Can I survive this, for how long, and can I expect to be cured?" You may have searched online for survival rate information. These ...

Non-muscle invasive bladder cancer is cancer that’s only in the inner lining of your bladder. It hasn’t grown into the muscle wall. Your doctor may also call it superficial bladder cancer, urothelial ...

JCO Precision Oncology Conversations features discussions with leading authors of JCO Precision Oncology articles, hosted by Dr. Abdul Rafeh Naqash. Join our experts in engaging conversations as they ...

ImmunityBio’s sBLA targets BCG-unresponsive papillary NMIBC without CIS, complementing the existing U.S. approval for CIS with or without papillary tumors. FDA interactions centered on updated ...